Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence

Autor: Bruno Vincenzi, Daniele Santini, Alice Zoccoli, Loretta D'Onofrio, Michele Iuliani, Francesco Pantano, Vladimir Virzì, Giuseppe Tonini, Giulia Ribelli, Luciano Stumbo, Chiara Spoto, Marco Fioramonti
Rok vydání: 2015
Předmět:
Oncology
Bone Neoplasms -- pathology -- secondary
medicine.medical_specialty
Pathology
Antineoplastic Agents -- pharmacology -- therapeutic use
medicine.medical_treatment
Antineoplastic Agents
Bone Neoplasms
Breast Neoplasms
Review
urologic and male genital diseases
Cell Proliferation -- drug effects
Bone remodeling
Breast cancer
Surgical oncology
Internal medicine
Diphosphonates -- pharmacology -- therapeutic use
medicine
Animals
Humans
Cell Proliferation
Early breast cancer
Bone Density Conservation Agents
Diphosphonates
business.industry
Sciences bio-médicales et agricoles
medicine.disease
Clinical trial
Bone Density Conservation Agents -- pharmacology -- therapeutic use
Clinical evidence
Female
business
Breast Neoplasms -- drug therapy -- pathology
Adjuvant
hormones
hormone substitutes
and hormone antagonists
Zdroj: Breast Cancer Research : BCR
Breast cancer research, 17
Popis: Bisphosphonates (BPs) are approved as standard therapy in breast cancer for the treatment of bone metastases, since they were demonstrated to reduce the prevalence of skeletal-related events including fractures and hypercalcemia. In the adjuvant setting, BPs can be given to prevent and treat tumor therapy-induced bone loss in premenopausal and postmenopausal women and, owing to their beneficial effect on bone turnover, have also been evaluated for prevention of bone metastases occurrence. In this article we will review the mechanisms through which BPs have been demonstrated to prevent premetastatic niche formation and cell proliferation in bone lesions. Moreover, preclinical evidence of antitumoral effects of BPs will be presented and results from the most important clinical trials will be described critically. BPs may clearly play a clinically important role in early breast cancer in a postmenopausal adjuvant setting.
info:eu-repo/semantics/published
Databáze: OpenAIRE
Externí odkaz: